| Drug ID: | Drug148 |
|---|---|
| Drug Name: | Upadacitinib |
| CID: | 58557659 |
| DrugBank ID: | DB15091 |
| Modality: | Small Molecule |
| Groups: | NULL |
| US Approved: | YES |
| Other Approved: | YES |
| Identifier: | NCT06780683, , NCT06274996, , NCT05782907, , NCT06095596, , NCT03653026, , NCT02819635, , NCT03345836, , NCT05867329 |
| Molecular Formula: | C17H19F3N6O |
| Molecular Weight: | 380.4 g/mol |
| Isomeric SMILES: | CC[C@@H]1CN(C[C@@H]1C2=CN=C3N2C4=C(NC=C4)N=C3)C(=O)NCC(F)(F)F |
| Synonyms: | Upadacitinib; ABT-494; Rinvoq; Upadacitinib anhydrous; UNII-4RA0KN46E0; 4RA0KN46E0; ABT 494; ABBV-599 COMPONENT UPADACITINIB; 1-Pyrrolidinecarboxamide, 3-ethyl-4-(3H-imidazo(1,2-a)pyrrolo(2,3-e)pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)-, (3S,4R)-; REL-(-)-(3S,4R)-3-ETHYL-4-(3H-IMIDAZO(1,2-A)PYRROLO(2,3-E)PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE |
| Phase 0: | 1 |
| Phase 1: | 6 |
| Phase 2: | 17 |
| Phase 3: | 49 |
| Phase 4: | 10 |
| Description: | NULL |
Molecular Structure
Knowledge Graph
| dtID | CID | Compound Name | Gene ID | Gene Name | Species | PubMed IDs | Action |
|---|---|---|---|---|---|---|---|
| dt1172 | 58557659 | Upadacitinib | 3718 | JAK3 | Homo sapiens (human) | None | |
| dt1173 | 58557659 | Upadacitinib | 3718 | JAK3 | Homo sapiens (human) | Inhibitor | |
| dt1174 | 58557659 | Upadacitinib | 3716 | JAK1 | Homo sapiens (human) | Inhibition | |
| dt1175 | 58557659 | Upadacitinib | 3717 | JAK2 | Homo sapiens (human) | Inhibition | |
| dt1176 | 58557659 | Upadacitinib | 3718 | JAK3 | Homo sapiens (human) | Inhibition | |
| dt1177 | 58557659 | Upadacitinib | 7297 | TYK2 | Homo sapiens (human) | Inhibitor | |
| dt1178 | 58557659 | Upadacitinib | 1565 | CYP2D6 | Homo sapiens (human) | None | |
| dt1179 | 58557659 | Upadacitinib | 3716 | JAK1 | Homo sapiens (human) | None |
- No data available
Phase Distribution
Phase Description
- Phase 0: Exploratory trials to assess drug behavior in humans
- Phase 1: Safety trials to determine safe dosage range
- Phase 2: Efficacy trials to evaluate therapeutic effects
- Phase 3: Large-scale trials to confirm efficacy and safety
- Phase 4: Post-marketing surveillance for long-term safety and efficacy
| Trial ID | Title | Phase | Status | Sponsor | Indications | Interventions | |
|---|---|---|---|---|---|---|---|
| NCT07442045 | Real-World Effectiveness and Safety of Upadacitinib Plus Vedolizumab vs Upadacitinib Monotherapy During Induction in Moderate-to-Severe Ulcerative Colitis | NULL | RECRUITING | Sixth Affiliated Hospital, Sun Yat-sen University | Ulcerative Colitis (UC) | DRUG: Upadacitinib|DRUG: Vedolizumab | Details |
| NCT05496348 | Study of Oral Upadacitinib to Assess Change in Disease Activity in Adult Participants With Ulcerative Colitis | NULL | RECRUITING | AbbVie | Ulcerative Colitis | None | Details |
| NCT05494606 | An Observational Study to Assess Change in Disease Activity and Adverse Events of Upadacitinib in Adult Participants With Moderate to Severe Ulcerative Colitis (UC) in Real-World Practice | NULL | ACTIVE_NOT_RECRUITING | AbbVie | Ulcerative Colitis | None | Details |
| NCT07138898 | Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty | PHASE2 | NOT_YET_RECRUITING | NYU Langone Health | Rheumatic Disease | DRUG: Methotrexate|DRUG: Sulfasalazine|DRUG: Hydr… | Details |
| NCT07073079 | A Study to Assess the Effectiveness of Second-Line Therapy of Upadacitinib and Risankizumab in Adult Participants With Crohn's Disease in a Real-World Setting | NULL | RECRUITING | AbbVie | Crohn's Disease | None | Details |
| NCT03653026 | A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Ulcerative Colitis | PHASE3 | COMPLETED | AbbVie | Ulcerative Colitis (UC) | DRUG: Placebo|DRUG: Upadacitinib | Details |
| NCT06922331 | Upadacitinib for Refractory IBD in Asian Children and Elderly: Age-Stratified Analysis | NULL | COMPLETED | Sixth Affiliated Hospital, Sun Yat-sen University | Crohn's Disease (CD)|Ulcerative Colitis (UC)|… | DRUG: Upadacitinib | Details |
| NCT03345849 | A Study of the Efficacy and Safety of Upadacitinib in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Conventional and/or Biologic Therapies | PHASE3 | COMPLETED | AbbVie | Crohn's Disease | DRUG: Upadacitinib|DRUG: Placebo for Upadacitinib | Details |
| NCT03345836 | A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Biologic Therapy | PHASE3 | COMPLETED | AbbVie | Crohn's Disease | DRUG: Matching Placebo for Upadacitinib|DRUG: Upa… | Details |
| NCT03345823 | A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433 | PHASE3 | ACTIVE_NOT_RECRUITING | AbbVie | Crohn's Disease | DRUG: Upadacitinib|DRUG: Placebo for Upadacitinib | Details |
| NCT03006068 | A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) | PHASE3 | ACTIVE_NOT_RECRUITING | AbbVie | Ulcerative Colitis (UC) | DRUG: Upadacitinib (ABT-494)|DRUG: Placebo | Details |
| NCT06838845 | An Observational Study to Evaluate Effectiveness and Safety of Upadacitinib in Chinese Adult Participants With Moderate to Severely Active Ulcerative Colitis (UC) | NULL | RECRUITING | AbbVie | Ulcerative Colitis | None | Details |
| NCT02819635 | A Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis (UC) | PHASE2|PHASE3 | COMPLETED | AbbVie | Ulcerative Colitis (UC) | DRUG: Placebo|DRUG: Upadacitinib | Details |
| NCT02782663 | A Study to Evaluate the Long-Term Efficacy, Safety, and Tolerability of Repeated Administration of Upadacitinib (ABT-494) in Participants With Crohn's Disease | PHASE2 | COMPLETED | AbbVie | Crohn's Disease (CD) | DRUG: ABT-494 | Details |
| NCT06780683 | Efficacy and Safety of Upadacitinib in Inflammatory Bowel Disease | NULL | RECRUITING | Xiang Gao | Inflammatory Bowel Disease|Crohn's Disease|Ulcera… | DRUG: Upadacitinib | Details |
| NCT06660693 | Comparison of Medical RESCUE Strategies for Patients With Steroid-refractory Acute Severe Ulcerative Colitis | PHASE3 | RECRUITING | McMaster University | Colitis, Ulcerative | DRUG: Upadacitinib Oral Product | Details |
| NCT06581042 | Study to Assess Treatment Patterns and Outcomes With Upadacitinib in Adult Participants With Inflammatory Bowel Disease in Belgium | NULL | RECRUITING | AbbVie | Ulcerative Colitis|Crohn's Disease | None | Details |
| NCT06573944 | IUS Predicts Upadacitinib Efficacy in Patients With Moderate to Severe Crohn's Disease：a Prospective Study | NULL | UNKNOWN | The Third Xiangya Hospital of Central South University | Crohn's Disease|Upadacitinib|Intestinal Ultrasoun… | None | Details |
| NCT06520397 | Efficacy and Safety of Dual-targeted Therapy With Upadacitinib and Ustekinumab Versus Intensified Ustekinumab Therapy in Crohn's Disease | PHASE4 | RECRUITING | Sixth Affiliated Hospital, Sun Yat-sen University | Crohn Disease | DRUG: Ustekinumab and Upadacitinib|DRUG: Ustekinu… | Details |
| NCT06498167 | Active Pharmacovigilance Study of the Medicine Rinvoq™ (Upadacitinib) | NULL | RECRUITING | Universidade do Porto | Inflammatory Disease|Drug Side Effect|Drug Use|Ad… | DRUG: Upadacitinib | Details |
| Disease ID | Disease Name | Definition | Category | Related Drugs | Mechanism | |
|---|---|---|---|---|---|---|
| No data available | ||||||
| Strategy ID | Therapeutic Strategy | Synonyms | Related Drugs | Mechanism | |
|---|---|---|---|---|---|
| S07 | Blockade of cytokine | Cytokine signalling | apremilast; roflumilast; filgotinib; tofacitinib; ABT494; ABT-874; ustekinumab; isankizumab; LY-2525623; AMG139; MEDI2079; guselkumab | Various T-cell subsets, their differentiation pathways and … | Details |
Pharmacokinetics of Upadacitinib in Healthy Subjects and Subjects With Rheumato…
PMID: 31701537
Year: 2020
Relationship Type:
Treatment
Score: 7.5
Upadacitinib (ABT-494) is a selective Janus kinase (JAK)1 inhibitor being developed for treatment of several inflammatory disorders. A population pha…
Successful Use of Upadacitinib, a Selective JAK Inhibitor, in the Treatment of …
PMID: 40689111
Year: 2025
Relationship Type:
Treatment
Score: 6.5
PURPOSE: Immunomodulatory agents, including conventional immunosuppressive treatment and biologics, are the mainstay of treating chronic uveitis. Jan…
Efficacy and safety of upadacitinib for patients with immune-mediated inflammat…
PMID: 40666511
Year: 2025
Relationship Type:
Treatment
Score: 6.5
OBJECTIVE: There is a growing array of options for the treatment of immune-mediated inflammatory diseases (IMIDs). To explore upadacitinib's efficacy…
Management of comorbid Crohn's disease and alopecia universalis with upadacitin…
PMID: 40625127
Year: 2025
Relationship Type:
Treatment
Score: 6.5
PURPOSE: This study describes the use of upadacitinib, a JAK1 inhibitor, in combination with oral minoxidil for treatment of alopecia universalis (AU…
Upadacitinib-Induced Hemolysis in a Patient With Glucose-6-Phosphate Dehydrogen…
PMID: 40568996
Year: 2025
Relationship Type:
Mechanism
Score: 6.5
Glucose-6-phosphate-dehydrogenase (G6PD) deficiency is a heterogenous disorder that may lead to severe hemolytic events with the ingestion of fava be…
Patients with Crohn's Disease and Ileostomy Can Respond to Upadacitinib
PMID: 40515784
Year: 2025
Relationship Type:
Treatment
Score: 6.5
BACKGROUND: Recent studies have established a role for Janus kinase (JAK) inhibitors in the management of patients with inflammatory bowel disease. H…
Upadacitinib for ulcerative colitis and pyoderma gangrenosum in a patient with …
PMID: 40495949
Year: 2025
Relationship Type:
Treatment
Score: 6.5
BACKGROUND: Pyoderma gangrenosum (PG) is one of the most severe extra-intestinal manifestations of ulcerative colitis (UC). The treatment of refracto…
Upadacitinib and vedolizumab combination therapy for the management of refracto…
PMID: 40490017
Year: 2025
Relationship Type:
Treatment
Score: 6.5
BACKGROUND/AIMS: Inflammatory bowel disease (IBD) is characterised by chronic inflammation of the gastrointestinal tract, and encompasses both ulcera…
Achievement of long-term treatment goals in upadacitinib-treated patients with …
PMID: 40488552
Year: 2025
Relationship Type:
Treatment
Score: 6.5
BACKGROUND AND AIMS: Comprehensive disease control is an important yet elusive treatment goal in ulcerative colitis (UC). We evaluated the effect of …
Upadacitinib as Rescue Therapy in a Pregnant Patient With IBD
PMID: 40370416
Year: 2025
Relationship Type:
Treatment
Score: 6.5
Upadacitinib is an oral Janus kinase inhibitor approved to treat moderate-to-severe ulcerative colitis. Studies have shown that upadacitinib is highl…
Long-term efficacy and safety of upadacitinib in patients with moderately to se…
PMID: 40347957
Year: 2025
Relationship Type:
Treatment
Score: 6.5
BACKGROUND: The U-ACTIVATE long-term extension study aims to evaluate the long-term efficacy and safety of upadacitinib in patients with moderately t…
Intensified Upadacitinib Dosing for Adolescent Patients with Acute Severe Ulcer…
PMID: 40310056
Year: 2025
Relationship Type:
Treatment
Score: 6.5
Background/Objectives: In adolescent patients with ulcerative colitis refractory to anti-tumor necrosis factor (TNF) therapy, episodes of acute sever…
Real-World Effectiveness and Safety of Upadacitinib in Patients with Ulcerative…
PMID: 40217680
Year: 2025
Relationship Type:
Treatment
Score: 6.5
Background/Objectives: Evidence is needed on the real-world outcomes of upadacitinib in patients with ulcerative colitis. This systematic review and …
Efficacy of Upadacitinib Induction Treatment in Moderate-to-Severe Ulcerative C…
PMID: 40095725
Year: 2025
Relationship Type:
Treatment
Score: 6.5
Background: Upadacitinib (UPA) is a new oral selective Janus Kinase (JAK) inhibitor that has shown high efficacy in the treatment of ulcerative colit…
Upadacitinib Results in Endoscopic Remission in Patients With Inflammatory Bowe…
PMID: 40063408
Year: 2025
Relationship Type:
Treatment
Score: 6.5
GOALS: Assess the safety and effectiveness of upadacitinib in patients with prior tofacitinib failure. BACKGROUND: Patients with severe, refractory C…
Real-World Effectiveness and Safety of Upadacitinib in Crohn's Disease: A Multi…
PMID: 40058746
Year: 2025
Relationship Type:
Treatment
Score: 6.5
BACKGROUND & AIMS: We aimed to describe the real-world effectiveness and safety of upadacitinib (UPA), an oral Janus kinase 1 inhibitor, in patients …
Effectiveness and Safety of Upadacitinib Induction Therapy for 223 Patients Wit…
PMID: 40038887
Year: 2025
Relationship Type:
Treatment
Score: 6.5
BACKGROUND: Real-world effectiveness and safety of upadacitinib in patients with Crohn's disease (CD) remain unclear. AIMS: This study aimed to evalu…
Advanced Combination Therapy with Biologics and Upadacitinib in Refractory Infl…
PMID: 40026313
Year: 2025
Relationship Type:
Treatment
Score: 6.5
BACKGROUND: Refractory inflammatory bowel disease (IBD) remains challenging despite the availability of various biologics. Advanced combination thera…
Disproportionality analysis of upadacitinib-related adverse events in inflammat…
PMID: 40008128
Year: 2025
Relationship Type:
Treatment
Score: 6.5
BACKGROUND: Upadacitinib, a Janus kinase inhibitor, has been increasingly used over the past few years to treat moderate to severe ulcerative colitis…
Rapid Resolution of Perianal Crohn's Disease with Upadacitinib
PMID: 39963477
Year: 2025
Relationship Type:
Treatment
Score: 6.5
A 20-year-old woman with ileocolonic, stricturing, and penetrating Crohn's disease (CD) presented with new onset perianal and vulvar CD despite havin…